Related Experiment Video

Updated: Aug 9, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial

Yongwhi Park1, Francesco Franchi2, Fabiana Rollini2

  • 1University of Florida College of Medicine-Jacksonville, Jacksonville, FL; Division of Cardiology, Department of Medicine, Gyeongsang National University Hospital, Jinju, Korea.

Trends in Cardiovascular Medicine
|September 23, 2015
PubMed

Insights

Patients with non-ST segment elevation myocardial infarction (NSTEMI) need better treatments to prevent recurrent atherothrombotic events. Newer antiplatelet drugs and longer treatment durations show promise but increase bleeding risks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Patients with non-ST segment elevation myocardial infarction (NSTEMI) face high risks of recurrent atherothrombotic events.
  • Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard but often insufficient, leading to thrombotic complications.
  • There is a need for more potent antithrombotic strategies for long-term prevention in NSTEMI patients.

Purpose of the Study:

  • To review current antithrombotic therapies for secondary prevention in NSTEMI patients.
  • To discuss novel agents and prolonged treatment durations for reducing ischemic events.
  • To highlight the balance between efficacy and bleeding risk with intensified antithrombotic regimens.

Main Methods:

  • Review of current literature on antithrombotic therapies for NSTEMI.
  • Analysis of novel P2Y12 inhibitors (prasugrel, ticagrelor), PAR-1 inhibitors (vorapaxar), and Factor Xa inhibitors (rivaroxaban).
  • Evaluation of strategies involving prolonged or intensified antiplatelet therapy beyond one year.

Main Results:

  • Novel agents and prolonged DAPT can reduce ischemic events in NSTEMI patients.
  • Intensified antithrombotic regimens increase the risk of bleeding complications.
  • The optimal balance between reducing ischemic events and minimizing bleeding remains a key consideration.

Conclusions:

  • Current antithrombotic strategies for NSTEMI secondary prevention are evolving.
  • More potent agents and extended treatment durations offer improved efficacy but require careful risk-benefit assessment.
  • Future research should focus on personalized antithrombotic approaches for NSTEMI patients.

Keywords:
Non-ST segment elevation myocardial infarctionOral antithrombotic therapy

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.5K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

709

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...